Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96686 | 1.00 | CHRM2 (0.55) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL15170714 | 0.88 | — | — | |
| SCHEMBL173191 | 0.88 | — | — | |
| SCHEMBL96778 | 0.82 | CHRM2 (0.40) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL13570076 | 0.82 | CHRM2 (0.40) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL12017242 | 0.79 | CHRM1 (0.58) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL13300984 | 0.79 | CHRM1 (0.58) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL9094744 | 0.79 | CHRM1 (0.58) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL24854140 | 0.77 | CHRM2 (0.52) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL9097759 | 0.76 | CHRM1 (0.55) | CHRM2CHRM1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757604-B1 | PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT | ASTELLAS PHARMA INC (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | CHRM2 358/4885CHRM1 352/4885CYP2D6 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.